National Cancer Institute
Epidemiology and Genomics Research
July 2014


About Us

Funding Opportunity
Outstanding Investigator Award (R35)
Application due date: October 20, 2014. AIDS Application Due Date: January 7, 2015
Job OpportunitiesJobOpportunity
Deadline to submit letter of intent: September 15, 2014
Upcoming Seminars & WorkshopsEvents
Science of Team Science Conference
August 6-8, 2014, in Austin, TX

August 11-15, 2014 in Boston, MA

IEA World Congress of Epidemiology
August 17-21, 2014 in Anchorage, AK

International Society for Environmental Epidemiology
August 24-28, 2014 in Seattle, WA
  • NIH Pre-Conference Workshop: Navigating the NIH funding system- planning, submitting and obtaining your first grant: August 24th, 1-4:30 PM 
International Genetic Epidemiology Society
August 28-30, 2014, in Vienna, Austria

American College of Epidemiology
September 7-9, 2014 in Silver Spring, MD

June 2-4, 2015, in Rotterdam, Netherlands
Abstracts due October 10, 2014
Blog Postsblogposts
Formula for Innovation: People + Ideas + Time
Drs. Francis Collins and Sally Rockey - NIH Director's Blog

How do Multi-PI Applications Fare?
Dr. Sally Rockey - Rock Talk
The Epidemiology and Genomics Research Program (EGRP) in the Division of Cancer Control and Population Sciences (DCCPS) funds research in human populations to understand the causes of cancer and related outcomes.

The Program fosters interdisciplinary collaborations, as well as the development and use of resources and technologies to advance cancer research and translation of this research, which serve as the basis for clinical and public health interventions.
Send Us Your IdeasSendUsYourIdeas
EGRP encourages readers to submit items of interest to Cancer Epidemiology Matters E-News.  EGRP reserves the right to decide whether or not materials are appropriate for inclusion.
Contact UsContactUs
Epidemiology and Genomics Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
9609 Medical Center Drive
4 East, MSC 9763
Bethesda, MD  20892
(240) 276-6730

For UPS, FedEx, and courier services, please use:
Rockville, MD  20850

New Webinar Series Begins in August; Focuses on Advancing Methods for Transforming Epidemiology ResearchTEAMWebinarSeries 

The Epidemiology and Genomics Research Program (EGRP) is launching a new webinar series, "Transforming Epidemiology through Advanced Methods (TEAM): Bringing the epidemiology community together as a virtual TEAM." The first webinar will be held in late August, and others are scheduled for October 2014 and January 2015.


The TEAM webinars will create an online community where epidemiologists can discuss methods, practices, and technologies that can improve the efficiency of practice and extend the reach of epidemiology in the 21st century.  


Webinar Dates, Topics, and Speakers

August 27, 2014, 12:00 - 1:00 p.m. (EDT) 

Dana E. Rollison, Ph.D.  

Vice President, Chief Health Information Officer

Associate Member, Department of Cancer Epidemiology

Moffitt Cancer Center, Tampa, FL 

Topic: "MyMoffitt Portal: Giving Data Back to Participants and Keeping Participants Engaged"


October 29, 2014, 12:00 - 1:00 p.m. (EDT) 

James Lacey, Jr., Ph.D. 

Associate Professor, Cancer Etiology  

City of Hope Cancer Center, Duarte, CA

Topic: "Modernizing the California Teachers Health Study Using a Tablet Based Tracking System: An All-in-One coordinating Center"


January 14, 2015, 12:00 - 1:00 p.m. (EST)

David Miller, Jr., M.D.   

Associate Professor, Internal Medicine

Wake Forest University, Winston-Salem, NC 

Topic: "Tools to Facilitate Surveys and Follow-Up Reminders for Subsequent Visits and Screenings"


Note: Additional speakers and topics may be added in the future.


Anyone who is interested is welcome to participate in the TEAM webinars. Each webinar will last approximately 30 minutes, and will be followed by 30 minutes of discussion moderated by EGRP staff. The webinars are free, but advance registration is required for each session. Instructions  for connecting to the webinars will be sent to all registrants.  


View the webinar Web page for more information. Questions about the series may be submitted to the Planning Committee at

Chronic inflammation is recognized as an important etiologic factor for several cancers. Past investigations of inflammation and cancer have been been limited or have included only a narrow range of analytes. Recently developed multiplex technologies can measure large numbers of immune/inflammatory markers using serum, plasma, and other specimens. These tools have created the opportunity for systematic, large-scale epidemiological studies to evaluate the role of inflammation in cancer. However, lack of consensus on the best assays to use, their performance characteristics, and how different assays relate to each other has hindered progress.


Microscopic view of a group of macrophages. Macrophages contribute to tumor growth and progression.
Source: Getty Images

To address these challenges, EGRP and the Division of Cancer Epidemiology and Genetics (DCEG) co-sponsored a workshop on "Using Immune Marker Panels to Uncover the Role of Inflammation in Cancer." Epidemiologists, immunologists, statisticians, and laboratory scientists gathered June 4-5, 2014, to describe their experiences with new inflammation marker technologies for multiplexing and to share findings from association studies using such methods. The presentations were organized around four themes:

  • Ongoing studies with inflammatory marker panel assays and disease associations in prospective cohorts
  • Biologic interpretation of marker association studies
  • State-of-the-science on multiplexed inflammation marker platforms/assays 
  • Statistical issues in multiplex inflammation panel studies
After the plenary sessions, participants formed break-out groups to identify research gaps and strategize approaches for future research. Key recommendations from these groups include the following: 
  • Identify and catalog ideal specimen types for examining inflammation markers.
  • Promote data sharing to enable comparison of data across platforms and optimization of study designs.
  • Encourage and facilitate interdisciplinary research to more fully develop multiplex inflammation technologies that can yield meaningful biologic insights.
  • Develop and/or refine assays to more reliably assay markers and more fully understand what is being measured. 
  • Establish means for validating biomarkers and multiplex assays.

Ongoing discussions among various research disciplines should accelerate the pace of development in this field and minimize the duplication of efforts. More information, including the full workshop agenda listing all speakers and their topics is available on the workshop Web page.  

The What and Why of the NIH Public Access PolicyNIHPublicAccess
The NIH Public Access Policy was developed to enhance and allow public access to the published results of scientific studies funded by the National Institutes of Health (NIH). The policy requires NIH-funded investigators to submit their final, peer-reviewed manuscripts to the PubMed Central digital archive immediately upon acceptance for publication, and the papers must be accessible to the public through PubMed Central no later than 12 months after publication.


NIH Public Access Policy Website: 


This policy has led to increased access to the results of NIH-funded research by both scientists and the public. On a typical weekday, 1 million users retrieve over 1.65 million articles from PubMed Central. This increased access to scientific publications undoubtedly advances the NIH's goal of improving human health.  

To increase investigator adherence to the public access policy, the NIH is now delaying non­competing continuation awards if publications arising from the award are not in compliance with the policy. The details of these efforts can be found in the NIH Guide for Grants and Contracts Notice NOT-OD-12-160. General information, guidance, and tutorials regarding the NIH public access policy may be found on the NIH Public Access website.


Adhering to the Public Access Policy

  • The new NIH submission applicability tool can help bring papers into compliance with the least effort. 
  • Investigators should submit papers to the NIH Manuscript Submission System (NIHMS) as soon as they are accepted for publication. Each manuscript will be assigned a unique NIHMS ID number.
  • Because the NIHMS ID is valid for only 3 months following the publication date, investigators should track the status of their publications using My NCBI's My Bibliography feature at least quarterly. 
  • Only those publications that resulted from NIH-funded research must be submitted; investigators must also report these papers in the publications section of their progress report.
  • The NIH website has pages with answers to FAQs about the public access policy and a glossary.   
This email was sent to by 

Epidemiology and Genomics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute | 9609 Medical Center Drive | 4 East, MSC 9763 | Bethesda | MD 20892

Contact Us | Privacy Policy | Accessibility | FOIA

U.S. Department of Health and Human Services
National Institutes of Health | National Cancer Institute |